Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

State Medicaid Programs Unlikely To Supplement Part D, Kaiser Analyst Says

Executive Summary

Most states are not planning to supplement the Medicare Part D program through Medicaid, Kaiser Commission on Medicaid & the Uninsured Associate Director Jocelyn Guyer said March 29

You may also be interested in...



States Consider Medicaid Drug Cuts Ahead Of Medicare Part D

State Medicaid programs are considering whether to discontinue coverage of certain drugs to avoid "wrapping around" Medicare Part D benefits in 2006

States Consider Medicaid Drug Cuts Ahead Of Medicare Part D

State Medicaid programs are considering whether to discontinue coverage of certain drugs to avoid "wrapping around" Medicare Part D benefits in 2006

Medicare Rx Plans Should Cover All Drugs During Start-Up, CMS Says

Medicare Rx plans will be expected to provide new enrollees a one-time prescription for drugs not on formulary to ease the transition into Part D, the Centers for Medicare & Medicaid Services says

Topics

UsernamePublicRestriction

Register

PS045620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel